These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24316434)

  • 21. Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease.
    Wilkins HM; Swerdlow RH
    Curr Top Med Chem; 2016; 16(8):849-57. PubMed ID: 26311426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium.
    Duara R; Barker W; Loewenstein D; Bain L
    Alzheimers Dement; 2009 Jan; 5(1):66-74. PubMed ID: 19118811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease.
    Aliyev A; Chen SG; Seyidova D; Smith MA; Perry G; de la Torre J; Aliev G
    J Neurol Sci; 2005 Mar; 229-230():285-92. PubMed ID: 15760652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans.
    Barrett DW; Gonzalez-Lima F
    Neuroscience; 2013 Jan; 230():13-23. PubMed ID: 23200785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can mild cognitive impairment be stabilized by showering brain mitochondria with laser photons?
    de la Torre JC; Olmo AD; Valles S
    Neuropharmacology; 2020 Jul; 171():107841. PubMed ID: 31704275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease.
    Hung CH; Ho YS; Chang RC
    Ageing Res Rev; 2010 Oct; 9(4):447-56. PubMed ID: 20553970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease.
    Cardoso S; Seiça RM; Moreira PI
    Expert Rev Neurother; 2017 Jan; 17(1):77-91. PubMed ID: 27366815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations.
    Szabados T; Dul C; Majtényi K; Hargitai J; Pénzes Z; Urbanics R
    Behav Brain Res; 2004 Sep; 154(1):31-40. PubMed ID: 15302108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cognitive and neural expression of semantic memory impairment in mild cognitive impairment and early Alzheimer's disease.
    Joubert S; Brambati SM; Ansado J; Barbeau EJ; Felician O; Didic M; Lacombe J; Goldstein R; Chayer C; Kergoat MJ
    Neuropsychologia; 2010 Mar; 48(4):978-88. PubMed ID: 19954747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rethinking Alzheimer's disease therapy: are mitochondria the key?
    Ankarcrona M; Mangialasche F; Winblad B
    J Alzheimers Dis; 2010; 20 Suppl 2():S579-90. PubMed ID: 20463405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative damage in mild cognitive impairment and early Alzheimer's disease.
    Lovell MA; Markesbery WR
    J Neurosci Res; 2007 Nov; 85(14):3036-40. PubMed ID: 17510979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
    Sahni JK; Doggui S; Ali J; Baboota S; Dao L; Ramassamy C
    J Control Release; 2011 Jun; 152(2):208-31. PubMed ID: 21134407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nutritional approaches in the risk reduction and management of Alzheimer's disease.
    Mi W; van Wijk N; Cansev M; Sijben JW; Kamphuis PJ
    Nutrition; 2013 Sep; 29(9):1080-9. PubMed ID: 23756280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against neurodegeneration with low-dose methylene blue and near-infrared light.
    Gonzalez-Lima F; Auchter A
    Front Cell Neurosci; 2015; 9():179. PubMed ID: 26029050
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of methylene blue and its metabolite - azure I - on bioenergetic parameters of intact mice brain mitochondria].
    Gureev AP; Samoylova NA; Potanina DV; Popov VN
    Biomed Khim; 2021 Nov; 67(6):485-490. PubMed ID: 34964442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcranial photobiomodulation (laser) therapy for cognitive impairment: A review of molecular mechanisms and potential application to canine cognitive dysfunction (CCD).
    Dewey CW; Brunke MW; Sakovitch K
    Open Vet J; 2022; 12(2):256-263. PubMed ID: 35603072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-level light therapy of the eye and brain.
    Rojas JC; Gonzalez-Lima F
    Eye Brain; 2011; 3():49-67. PubMed ID: 28539775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photobiomodulation for the aging brain.
    Cardoso FDS; Gonzalez-Lima F; Gomes da Silva S
    Ageing Res Rev; 2021 Sep; 70():101415. PubMed ID: 34325071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.